Completed Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track to submit a BLA ...

EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2 A2A-005 in ...

We plan to initiate the trial in Q2 2025 and expect to have data from the interim analysis ... And we were excited to see ...

At the ESMO conference, BioCity presented interim Phase 1 clinical ... At this point, we believe the company is well ...

Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position ...

The outcome of the primary endpoint of PFS is projected to be available in the first half of 2025, potentially followed by a BLA submission ... at the 2024 European Society of Medical Oncology (ESMO) ...

Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ETCompany ParticipantsBill Anderson - Chairman & CEOWolfgang Nickl ...

The company anticipates reporting initial clinical proof-of-concept data in the second half of 2025. BBI-825, a novel ... data was presented at the European Society for Medical Oncology (ESMO) ...

"The $9.2 million in cash proceeds received this month from the exercise of existing warrants has strengthened our balance sheet to extend beyond our PDUFA date and into 2025. We are now ... Society ...